Short answer
CYTOKINETICS INC (CYTK) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results covered the period ended March 31, 2026.
CYTOKINETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered the period ended March 31, 2026
- Full financial results and management commentary furnished in Exhibit 99.1
- May 5, 2026 announcement provides the market’s latest quarterly operating update
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue reached $19.4M, including $4.8M MYQORZO sales and an $11.9M Bayer milestone tied to first U.S. sale
- MYQORZO launch traction: 275+ prescribers, approximately 680 patients, and over 70% on paid prescriptions by March 31
- ACACIA-HCM met both primary endpoints, expanding aficamten’s potential into non-obstructive HCM pending full data and regulatory review
- FDA accepted MAPLE-HCM supplemental NDA with November 14, 2026 PDUFA date, creating a near-term regulatory catalyst
- Cash, equivalents and investments totaled approximately $1.1B, while Q1 net loss widened to $206.0M amid SG&A launch investment of $104.9M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CYTOKINETICS INC 8-K filings
Get the next CYTK 8-K as it lands
Follow CYTK for push alerts, or ask the research agent what this filing means.